Tema ETF Trust. Holdings as of May 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Revolution Medicines IncRVMD | 7.73% | $13.61M | 86,450 |
| Novartis AG | 4.03% | $9.09M | 47,020 |
| Eli Lilly & CoLLY | 4.82% | $8.49M | 7,684 |
| AstraZeneca PLC | 3.54% | $8.39M | 33,501 |
| Roche Holding AG | 4.21% | $7.42M | 141,653 |
| Cogent Biosciences IncCOGT | 4.10% | $7.22M | 206,419 |
| Immunome IncIMNM | 3.91% | $6.89M | 315,648 |
| Celcuity IncCELC | 3.58% | $6.31M | 47,450 |
| Merck & Co IncMRK | 3.57% | $6.29M | 52,978 |
| Nuvalent Inc | 3.37% | $5.93M | 53,763 |
| Bristol-Myers Squibb CoBMY | 3.30% | $5.81M | 101,680 |
| Legend Biotech CorpLEGN | 2.99% | $5.27M | 194,092 |
| AbbVie IncABBV | 2.81% | $4.94M | 22,700 |
| Exelixis IncEXEL | 2.78% | $4.89M | 96,885 |
| Bridgebio Pharma IncBBIO | 2.75% | $4.85M | 73,191 |
| Johnson & JohnsonJNJ | 2.55% | $4.48M | 19,900 |
| CG oncology IncCGON | 2.43% | $4.28M | 68,702 |
| Genmab A/SGMAB | 2.37% | $4.18M | 158,861 |
| Ideaya Biosciences IncIDYA | 2.27% | $4.00M | 135,847 |
| Amgen IncAMGN | 2.11% | $3.71M | 11,019 |
| Zai Lab LtdZLAB | 1.98% | $3.48M | 196,972 |
| BeOne Medicines LtdONC | 1.88% | $3.31M | 11,505 |
| Zymeworks IncZYME | 1.51% | $2.65M | 105,615 |
| Enliven Therapeutics IncELVN | 1.31% | $2.30M | 58,197 |
| Relay Therapeutics IncRLAY | 1.28% | $2.26M | 161,076 |
| Halozyme Therapeutics IncHALO | 1.23% | $2.17M | 32,598 |
| Summit Therapeutics IncSMMT | 1.21% | $2.12M | 121,097 |
| Arcus Biosciences IncRCUS | 1.20% | $2.11M | 83,140 |
| Gilead Sciences IncGILD | 1.12% | $1.98M | 14,692 |
| Immatics NV | 1.12% | $1.97M | 171,499 |
| First American Treasury ObligaCash or money market | 1.09% | $1.92M | 1,920,309 |
| Erasca IncERAS | 1.08% | $1.90M | 147,828 |
| Nuvation Bio IncNUVB | 1.07% | $1.89M | 395,313 |
| AnaptysBio IncANAB | 0.99% | $1.74M | 31,270 |
| UroGen Pharma LtdURGN | 0.93% | $1.65M | 58,518 |
| Guardant Health IncGH | 0.81% | $1.42M | 10,986 |
| Syndax Pharmaceuticals IncSNDX | 0.80% | $1.41M | 72,212 |
| Corvus Pharmaceuticals IncCRVS | 0.76% | $1.35M | 108,477 |
| Regeneron Pharmaceuticals IncREGN | 0.75% | $1.31M | 2,138 |
| ArriVent Biopharma IncAVBP | 0.73% | $1.29M | 42,744 |
| Iovance Biotherapeutics IncIOVA | 0.65% | $1.15M | 280,048 |
| Inhibrx Biosciences IncINBX | 0.60% | $1.06M | 10,170 |
| Olema Pharmaceuticals IncOLMA | 0.60% | $1.05M | 79,759 |
| Cullinan Therapeutics IncCGEM | 0.59% | $1.03M | 62,826 |
| Natera IncNTRA | 0.54% | $946.64K | 4,238 |
| First Tracks Biotherapeutics ITRAX | 0.53% | $932.37K | 58,419 |
| Immunocore Holdings PLCIMCR | 0.51% | $891.23K | 30,849 |
| BridgeBio Oncology TherapeuticBBOT | 0.48% | $837.25K | 93,339 |
| CytomX Therapeutics IncCTMX | 0.47% | $824.35K | 228,987 |
| HUTCHMED China LtdHCM | 0.44% | $776.57K | 67,823 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.